155 related articles for article (PubMed ID: 33604462)
1. Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.
Bolz S; Ramakrishnan T; Fleischer M; Livingstone E; Stolte B; Thimm A; Kizina K; Ugurel S; Kleinschnitz C; Glas M; Zimmer L; Hagenacker T
eNeurologicalSci; 2021 Mar; 22():100324. PubMed ID: 33604462
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
3. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
[TBL] [Abstract][Full Text] [Related]
4. Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.
Amylidi AL; Gogadis A; Yerolatsite M; Zarkavelis G; Torounidou N; Keramisanou V; Kampletsas E; Mauri D
Curr Oncol; 2023 Dec; 30(12):10509-10518. PubMed ID: 38132400
[TBL] [Abstract][Full Text] [Related]
5. Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor-Induced Hypophysitis.
Quandt Z; Kim S; Villanueva-Meyer J; Coupe C; Young A; Kang JH; Yazdany J; Schmajuk G; Rush S; Ziv E; Perdigoto AL; Herold K; Lechner MG; Su MA; Tyrrell JB; Bluestone J; Anderson M; Masharani U
J Endocr Soc; 2023 Feb; 7(4):bvad012. PubMed ID: 36860908
[TBL] [Abstract][Full Text] [Related]
6. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors.
Fukushima T; Kobayashi S; Ueno M
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38769817
[TBL] [Abstract][Full Text] [Related]
7. Myasthenia Gravis-Like Syndrome Resulting From Immune Checkpoint Inhibitors in a Patient With Urothelial Carcinoma.
Vivas AJ; Chaudhry U; Punchayil Narayanankutty N; Lopez R; Lamarche J
Cureus; 2024 May; 16(5):e60003. PubMed ID: 38854361
[TBL] [Abstract][Full Text] [Related]
8. Neurological complications of immune checkpoint inhibitors: what happens when you 'take the brakes off' the immune system.
Dalakas MC
Ther Adv Neurol Disord; 2018; 11():1756286418799864. PubMed ID: 30245744
[TBL] [Abstract][Full Text] [Related]
9. Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis.
Gullapalli M; Arulprakash N; Safar M; Kocurek E
Cureus; 2024 Apr; 16(4):e58651. PubMed ID: 38770481
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
Yu H; Wang X; Pan Y; Li H
J Neurol; 2024 Jun; ():. PubMed ID: 38864881
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
12. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
13. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
14. Sarcopenia and the risk of adverse events in patients treated with immune checkpoint inhibitors: a systematic review.
Guzman-Prado Y; Ben Shimol J; Samson O
Cancer Immunol Immunother; 2021 Oct; 70(10):2771-2780. PubMed ID: 33625531
[TBL] [Abstract][Full Text] [Related]
15. Myasthenia Gravis in Poland: National Healthcare Database Epidemiological Study.
Sobieszczuk E; Napiórkowski Ł; Szczudlik P; Kostera-Pruszczyk A
Neuroepidemiology; 2021 Feb; ():1-8. PubMed ID: 33611318
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy.
Kapoor M; Keh R; Compton L; Morrow S; Gosal D; Manji H; Reilly MM; Lunn MP; Lavin TM; Carr AS
J Neurol; 2021 Apr; 268(4):1485-1490. PubMed ID: 33608795
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory demyelinating polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC).
Bus SRM; Zambreanu L; Abbas A; Rajabally YA; Hadden RDM; de Haan RJ; de Borgie CAJM; Lunn MP; van Schaik IN; Eftimov F;
Trials; 2021 Feb; 22(1):155. PubMed ID: 33608058
[TBL] [Abstract][Full Text] [Related]
18. Unexpected pure red series aplastic anemia secondary to pembrolizumab treatment: a case report and literature review.
Meri-Abad M; Cunquero Tomás AJ; Jaime AB
Melanoma Res; 2021 Apr; 31(2):186-189. PubMed ID: 33625098
[TBL] [Abstract][Full Text] [Related]
19. In-depth peripheral CD4
Huan X; Luo S; Zhong H; Zheng X; Song J; Zhou L; Lu J; Wang Y; Xu Y; Xi J; Zou Z; Chen S; Zhao C
Ann Clin Transl Neurol; 2021 Apr; 8(4):749-762. PubMed ID: 33616296
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.
Apalla Z; Papageorgiou C; Lallas A; Delli F; Fotiadou C; Kemanetzi C; Lazaridou E
Dermatol Pract Concept; 2021 Jan; 11(1):e2021155. PubMed ID: 33614223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
